OM Holdings Limited has reported Q1 2025 production in line with guidance, completed a significant refinancing, and highlighted ongoing operational trials amid evolving market conditions for ferrosilicon and manganese.
Lumos Diagnostics reported a 21% quarter-on-quarter revenue increase in Q3 FY25, driven by strong product sales and expanded development agreements. The company also secured Medicare coverage in key US regions and advanced its pivotal FebriDx CLIA waiver study with FDA submission expected by year-end.